Skin protection behaviour and sex differences in melanoma location in patients with multiple primary melanomas

Warren, Matthew J.; McMeniman, Erin; Adams, Agnieszka; De’Ambrosis, Brian

doi:10.1111/ajd.12373

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, we found that subsequent CMMs in the same individual were thinner than the index CMM, in line with previous findings . This may be a result of increased awareness and skin surveillance contributing to earlier detection, rather than differences in biologic tumor aggressiveness . Interestingly, the Australian study by Youlden et al .…”

Section: Discussionsupporting

confidence: 91%

Reduced disease‐specific survival following a diagnosis of multiple primary cutaneous malignant melanomas—a nationwide, population‐based study

Utjés

Lyth

Lapins

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

Outcome data comparing patients with multiple primary invasive cutaneous malignant melanomas (MPMs) to single primary invasive cutaneous malignant melanomas (SPMs) show conflicting results. We have analyzed differences in disease-specific survival between these patients in a nationwide population-based setting. From the Swedish Melanoma Register, 27,235 patients were identified with a first invasive cutaneous malignant melanoma (CMM) between 1990 and 2007, followed-up through 2013. Of these, 700 patients developed MPMs. Cox proportional hazard regression was used for adjusted cause-specific hazard ratios (HRs). An interval of ≤5 years between CMM diagnoses was significantly correlated to a decreased CMM-specific survival in Stage I-II MPM- vs. SPM-patients (HR 1.32; 95% CI 1.04-1.67; p = 0.02). MPM-patients with longer time interval between diagnoses experienced similar risk of CMM-death as SPM-patients. The risk of CMM-death increased by almost 50% above the expected outcome according to stage of the index CMM by the diagnosis of a second CMM (HR 1.48; 95% CI 1.19-1.85; p < 0.001). MPM vs. SPM-patients had a worse outcome (HR 1.38; 95% CI 1.05-1.83; p = 0.001). This emphasizes the importance of prevention efforts in SPM-patients to decrease the risk of subsequent CMMs and has implications for more vigilant follow-up in MPM-patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Reduced disease‐specific survival following a diagnosis of multiple primary cutaneous malignant melanomas—a nationwide, population‐based study

Utjés

Lyth

Lapins

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The mean age at diagnosis is approximately 60 years, somewhat higher than that for SPM, and males are most frequently affected than females [7]. In most cases it is metachronous and arises in the trunk and the extremities in males and females, respectively [8]; approximately half of the subsequent lesions occur within the same anatomical region as the index melanoma [6, 7, 9, 10]. Decreasing tumor thickness in subsequent MPMs has been also reported and lower disease stage at diagnosis showed a positive prognostic significance, though outcome and survival was found not to depend on the total number of primary lesions [11, 12].…”

Section: Introductionmentioning

confidence: 99%

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

et al. 2019

View full text Add to dashboard Cite

Introduction Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant melanoma (CMM). They are often sporadic harbouring several somatic mutations, but also familial cases harbouring a CDKN2A germline mutation have been describe in Caucasian populations. The aim of this study was to investigate the incidence, the distribution patterns and the impact of known and unknown germline and somatic mutations in patients with MPM from Italy. Materials and methods One-hundred and two MPM patients were enrolled for germline mutation analysis, and five patients with at least four MPMs were identified for somatic mutation analysis. The demographic, pathologic and clinical features were retrieved from medical records. Molecular analysis for both germline and somatic mutations was performed in genomic DNA from peripheral blood and tissue samples, respectively, through a next generation sequencing approach, using a specific multiple-gene panel constructed by the Italian Melanoma Intergroup for somatic analysis and a commercial cancer hotspot panel for somatic analysis. Results CDKN2A mutations were detected in 6/16 (37.5%) and 3/86 (3.5%) MPM cases with and without family history for melanoma, respectively. Furthermore, multiple MC1R and, to a lesser extent, ATM variants have been identified. BAP1 variants were found only in MPM patients from southern Italy. The most frequent somatic variants were the pathogenic BRAF V600E and TP53 , followed by KIT, PIK3CA , KDR , and NRAS . Single APC, ERBB4, MET, JAK3 and other variants with unknown function were also detected. Conclusions CDNK2A mutation is the most relevant susceptibility mutation in Italian patients with MPM, especially those with a family history for CMM. The prevalence of this mutation and other sequence variants identified in this study varies among specific sub-populations. Furthermore, some heterogeneity in driver somatic mutations between sporadic MPMs has been observed, as well as in a number of associated sequence variants the clinical impact of which needs to be further elucidated. Electronic supplementary material The online version of this article (10.1186/s12885-019-5984-7) contains supplementary material, which is available to authorized users.

show abstract

“…7 The risk factors for the development of melanoma have been well described in numerous publications; with the number of common nevi, significant UV exposure, a family history of melanoma, age over 60 years and DNS being the most significant. 8 We present the unusual case of a patient with DNS and minimal family history of melanoma who developed a total of nine melanomas, eight of which were clustered within the peripartum up to 1-year postpartum period. The incidence of malignant melanoma is rare before puberty, then rises steeply through child-bearing years and decreases during menopausal years.…”

Section: Discussionmentioning

confidence: 99%

Cluster of pregnancy‐associated melanoma: A case report and brief update

Rooij

Adams

De’Ambrosis

et al. 2020

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Melanoma incidence is increasing globally with Australia having the highest incidence in the world. Pregnancy‐associated melanoma is recognized in the published work; however, significant knowledge deficiencies exist. We present the case of a 34‐year‐old woman with dysplastic nevus syndrome who over a 15‐year period developed a total of nine melanomas, with eight clustered around an 18‐month peri‐ to post‐partum period. The first eight lesions were in situ with the ninth lesion invasive. No metastatic disease was observed over the 18‐year follow‐up period. This case identifies the potential sensitivity of a subset of melanomas to pregnancy‐related factors, with particular relevance to the development of lesions in the post‐partum period. We suggest that patients with a history of any documented melanoma risk factors, particularly dysplastic nevus syndrome, require close monitoring especially during pregnancy and early post‐partum.

show abstract

Skin protection behaviour and sex differences in melanoma location in patients with multiple primary melanomas

Cited by 6 publications

References 16 publications

Reduced disease‐specific survival following a diagnosis of multiple primary cutaneous malignant melanomas—a nationwide, population‐based study

Reduced disease‐specific survival following a diagnosis of multiple primary cutaneous malignant melanomas—a nationwide, population‐based study

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

Cluster of pregnancy‐associated melanoma: A case report and brief update

Contact Info

Product

Resources

About